Mark R. Bamforth
Mark, who joined as an Operating Partner in 2018, is the founder and CEO of Ampersand portfolio company, Brammer Bio. Previously, Mark founded Gallus BioPharmaceuticals, a premier CDMO delivering clinical and commercial mammalian based biopharmaceuticals which was sold to DPx Holdings B.V. (Patheon) in September 2014. Mark spent 22 years in the UK and USA, running global operations and a pharmaceutical CMO business for Genzyme Corp. His work at Genzyme included supporting cell therapy and gene therapy clinical trials resulting in the first FDA approval of a cell therapy product. He serves on the MassBio Board and is a founding trustee of the Saltire Foundation. He holds a B.S. in Chemical Engineering from Strathclyde University and a M.B.A. from Henley Management College.